Global Information
회사소개 | 문의 | 비교리스트

세계의 시클로스포린 의약품 시장(2020-2026년)

Global Cyclosporine drugs Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949598
페이지 정보 영문
가격
US $ 3,600 ₩ 4,254,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,672,000 Printable PDF (Enterprise License)


세계의 시클로스포린 의약품 시장(2020-2026년) Global Cyclosporine drugs Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 시클로스포린 의약품 시장은 예측 기간 중 중간 정도의 CAGR로 성장할 것으로 추정되고 있습니다. 류마티스 관절염의 유병률 증가는 전 세계에서 시클로스포린 의약품의 수요를 창출할 것으로 기대되고 있습니다. 질병관리예방센터(CDC)는 2017년 3월 시점에 5440만 명의 미국인이 관절염을 앓고 있으며, 이것은 인구의 약 25%에 상당한다고 추정하고 있습니다. 관절염은 관절의 통증, 뻣뻣함, 붓기를 일으킵니다. 시클로스포린 의약품은 관절염의 통증과 붓기를 경감하고, 관절의 손상을 막을 수도 있습니다.

시클로스포린 의약품 시장을 조사했으며, 시장 개요, 시장 성장요인 및 저해요인 분석, 적응증별·투여 경로별·지역별 시장 규모의 추이와 예측, 경쟁 구도, 주요 기업의 개요, 시장 기회 등 정보를 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재의 시장 동향
  • 규칙과 규제

제3장 경쟁 구도

  • 회사 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Allergan PLC
    • Sun Pharmaceuticals Industries, Ltd.
    • Novartis AG
    • Teva Pharmaceuticals Industries, Ltd.
    • Apotex Inc.

제4장 시장 영향요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 시장 분석·예측 : 세분화별

  • 적응증별
    • 이식거부반응의 예방
    • 류마티스 관절염
    • 건선
    • 건조안
    • 자가면역성 중증근무력증
    • 기타
  • 투여 경로별
    • 경구
    • 비경구

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • AbbVie Inc.
  • Allergan PLC
  • Apotex, Inc.
  • Mayne Pharma Group Ltd.
  • Mckesson Medical Surgical Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Regenerx Biopharmaceuticals, Inc.
  • Santen Pharmaceuticals Co. Ltd.
  • Sun Pharmaceuticals Industries, Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceuticals Industries, Ltd.
  • United Biotech Pvt. Ltd.
KSA 20.07.31

LIST OF TABLES

  • 1. GLOBAL CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL RHEUTMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL PSORIASIS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL TRANSPLANT REJECTION PROPHYLAXIS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL DRY EYE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL AUTOIMMUNE MYASTHENIA GRAVIS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL OTHER INDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 9. GLOBAL ORAL MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL PARENTERAL MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 15. EUROPEAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. EUROPEAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 17. EUROPEAN CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD CYCLOSPORINE DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CYCLOSPORINE DRUGS MARKET SHARE BY INDICATION, 2019 VS 2026 (%)
  • 2. GLOBAL CYCLOSPORINE DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2019 VS 2026 (%)
  • 3. GLOBAL CYCLOSPORINE DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD CYCLOSPORINE DRUGS MARKET SIZE, 2019-2026 ($ MILLION)

Global Cyclosporine drugs Market Size, Share & Trends Analysis Report, by Indication (Rheumatoid Arthritis, Psoriasis, Transplant Rejection Prophylaxis, Dry Eye, Autoimmune Myasthenia Gravis and Other), by Route of Administration (Oral and Parenteral) and Forecast Period, 2020-2026

The global cyclosporine drug market is estimated to grow at a moderate CAGR during the forecast period. The rising prevalence of rheumatoid arthritis and transplant rejection prophylaxis is expected to create demand for cyclosporine drug across the globe. The Centers for Disease Control and Prevention (CDC), in March 2017, estimated that 54.4 million US adults suffer from arthritis - equating to about 25% of the population. Arthritis is the leading cause of disability and causes pain, aching, stiffness, and swelling of the joints. Cyclosporine drug decreases the pain and swelling of arthritis, and may also prevent joint damage and reduce the risk of long term disability.

The global cyclosporine drugs market is segmented based on indication and route of administration. Based on indication, the market is classified into rheumatoid arthritis, psoriasis, transplant rejection prophylaxis, dry eye, and autoimmune myasthenia gravis and others. Based on the route of administration, the market is classified into oral and parenteral. Geographically, the global Cyclosporine drugs market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The market in the Asia-Pacific region is estimated to grow significantly due to various factors such as an increase in awareness among the population, a rise in disposable income and improved healthcare sector.

The major companies providing cyclosporine drugs include Allergan PLC, Sun Pharmaceuticals Industries, Ltd. Novartis AG, Teva Pharmaceuticals Industries, Ltd., Apotex Inc., Otsuka Pharmaceutical Co. Ltd., Regenerx Biopharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd. These players are adopting various strategies in order to sustain in the global market. For instance, in May 2018, Teva Canada launched Teva-Cyclosporine ophthalmic emulsion, the first generic version of Restasis in Canada for the treatment of dry eye disease.

Research Methodology

The market study of the global cyclosporine drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Cyclosporine Drugs Market Research and Analysis by Indication
  • Global Cyclosporine Drugs Market Research and Analysis by Route of Administration

The Report Covers:

  • Comprehensive research methodologies of the global cyclosporine drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cyclosporine drugs market.
  • Insights about market determinants which are stimulating the global cyclosporine drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Allergan PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Sun Pharmaceuticals Industries, Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Novartis AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Teva Pharmaceuticals Industries, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Apotex Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Cyclosporine Drugs Market by Indication
    • 5.1.1. Transplant Rejection Prophylaxis
    • 5.1.2. Rheumatoid Arthritis
    • 5.1.3. Psoriasis
    • 5.1.4. Dry Eye
    • 5.1.5. Autoimmune Myasthenia Gravis
    • 5.1.6. Others
  • 5.2. Global Cyclosporine Drugs Market by Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Allergan PLC
  • 7.3. Apotex, Inc.
  • 7.4. Mayne Pharma Group Ltd.
  • 7.5. Mckesson Medical Surgical Inc.
  • 7.6. Novartis AG
  • 7.7. Otsuka Pharmaceutical Co. Ltd.
  • 7.8. Regenerx Biopharmaceuticals, Inc.
  • 7.9. Santen Pharmaceuticals Co. Ltd.
  • 7.10. Sun Pharmaceuticals Industries, Ltd.
  • 7.11. Takeda Pharmaceutical Co. Ltd.
  • 7.12. Teva Pharmaceuticals Industries, Ltd.
  • 7.13. United Biotech Pvt. Ltd.
Back to Top
전화 문의
F A Q